AtaiBeckley Inc. logo

AtaiBeckley Inc.

Stock
Stock
Ticker: ATAI
ATAI

Price

Price

CHART BY

Frequently asked questions

AtaiBeckley Inc.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -2.188. EPS indicates the company's profitability on a per-share basis.
Currently, 5 analysts cover AtaiBeckley Inc.'s stock, with a consensus target price of $7.875. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, AtaiBeckley Inc. reported a revenue of $4.47M.
AtaiBeckley Inc.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$145.50M. EBITDA measures the company's overall financial performance.
AtaiBeckley Inc. has a free cash flow of -$129.45M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
AtaiBeckley Inc. employs approximately 117 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.

Financials

EPS (TTM) 
-2.188
Revenue (TTM) 
$4.47M
EBITDA (TTM) 
-$145.50M
Free Cashflow (TTM) 
-$129.45M

Analyst Ratings

The price target is $7.875 and the stock is covered by 5 analysts.

Buy

1

Hold

4

Sell

0

Information

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

Employees
117
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
ATAI

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation